We expanded the current literature on assessing the association between short-term changes in plasma levels of p-tau181 and NfL and long-term cognitive and brain structure volume changes by using the ADNI data, with the focus on Aβ-positive patients who are the primary study population in AD drug development trials. This evidence concerns the gene NEFL and Alzheimer disease.